Baugh & Associates LLC Acquires 29,025 Shares of Pfizer Inc. (NYSE:PFE)

Baugh & Associates LLC boosted its position in Pfizer Inc. (NYSE:PFE - Free Report) by 17.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 194,168 shares of the biopharmaceutical company's stock after purchasing an additional 29,025 shares during the period. Pfizer accounts for about 2.6% of Baugh & Associates LLC's portfolio, making the stock its 15th biggest holding. Baugh & Associates LLC's holdings in Pfizer were worth $4,970,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Charles Schwab Investment Management Inc. raised its holdings in Pfizer by 11.0% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 130,143,942 shares of the biopharmaceutical company's stock worth $3,766,366,000 after purchasing an additional 12,864,343 shares during the last quarter. Marshall Wace LLP increased its position in shares of Pfizer by 279.3% during the second quarter. Marshall Wace LLP now owns 5,378,173 shares of the biopharmaceutical company's stock worth $150,481,000 after acquiring an additional 8,378,173 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in shares of Pfizer by 22.4% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 38,068,879 shares of the biopharmaceutical company's stock worth $1,101,713,000 after purchasing an additional 6,977,587 shares during the last quarter. International Assets Investment Management LLC purchased a new stake in Pfizer in the 3rd quarter valued at $146,481,000. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. lifted its position in shares of Pfizer by 164.2% during the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 7,316,405 shares of the biopharmaceutical company's stock valued at $211,737,000 after purchasing an additional 4,546,809 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company's stock.

Insider Buying and Selling

In other Pfizer news, Director Scott Gottlieb acquired 1,000 shares of the business's stock in a transaction dated Wednesday, October 30th. The stock was purchased at an average price of $28.24 per share, with a total value of $28,240.00. Following the transaction, the director now directly owns 10,000 shares in the company, valued at approximately $282,400. The trade was a 11.11 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 0.06% of the stock is owned by corporate insiders.

Pfizer Stock Down 0.7 %

Shares of PFE stock traded down $0.19 during midday trading on Monday, reaching $26.30. 35,146,711 shares of the stock were exchanged, compared to its average volume of 35,869,448. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The firm has a market cap of $149.06 billion, a PE ratio of 35.55, a price-to-earnings-growth ratio of 0.64 and a beta of 0.64. The company's 50 day moving average is $26.08 and its two-hundred day moving average is $27.99. Pfizer Inc. has a 1 year low of $24.48 and a 1 year high of $31.54.

Pfizer (NYSE:PFE - Get Free Report) last announced its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, beating analysts' consensus estimates of $0.64 by $0.42. The business had revenue of $17.70 billion during the quarter, compared to the consensus estimate of $14.92 billion. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The business's revenue for the quarter was up 31.2% on a year-over-year basis. During the same quarter last year, the firm earned ($0.17) earnings per share. On average, equities research analysts predict that Pfizer Inc. will post 2.94 EPS for the current year.

Pfizer Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, January 24th will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 6.54%. This is an increase from Pfizer's previous quarterly dividend of $0.42. The ex-dividend date is Friday, January 24th. Pfizer's dividend payout ratio (DPR) is currently 227.03%.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the company. UBS Group reduced their target price on Pfizer from $31.00 to $29.00 and set a "neutral" rating for the company in a report on Wednesday, January 8th. Citigroup assumed coverage on shares of Pfizer in a research note on Friday, October 25th. They set a "neutral" rating and a $30.00 price target on the stock. Sanford C. Bernstein began coverage on Pfizer in a research report on Thursday, October 17th. They issued a "market perform" rating and a $32.00 price target for the company. Evercore ISI upgraded shares of Pfizer to a "strong-buy" rating in a research note on Wednesday, October 30th. Finally, Wolfe Research began coverage on shares of Pfizer in a research note on Friday, November 15th. They issued an "underperform" rating and a $25.00 target price on the stock. One research analyst has rated the stock with a sell rating, eight have given a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat, Pfizer presently has an average rating of "Moderate Buy" and a consensus price target of $32.00.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.